Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723198 | 0.84 | IMPDH2 (0.37) | ARALDH1A1IMPDH2IMPDH1KDM4E | |
| SCHEMBL2725596 | 0.83 | IMPDH2 (0.39) | ALDH1A1IMPDH2IMPDH1MEP1BAOC3 | |
| SCHEMBL15210186 | 0.82 | HTR2A (0.34) | ARALDH1A1IMPDH2IMPDH1KDM4E | |
| SCHEMBL13547954 | 0.82 | KDM4E (0.36) | ARALDH1A1IMPDH2IMPDH1KDM4E | |
| SCHEMBL9723151 | 0.80 | AR (0.37) | ARKDM4EAOC3SLC22A12CYP11B1 | |
| SCHEMBL17604488 | 0.79 | KDM4E (0.42) | ARALDH1A1IMPDH2IMPDH1KDM4E | |
| SCHEMBL3839278 | 0.79 | ALDH1A1 (0.37) | ARALDH1A1IMPDH2IMPDH1KDM4E | |
| SCHEMBL18854488 | 0.79 | GPR35 (0.37) | ARALDH1A1IMPDH2IMPDH1KDM4E | |
| SCHEMBL29472380 | 0.78 | CYP11B1 (0.40) | ARALDH1A1IMPDH2IMPDH1KDM4E | |
| SCHEMBL28574963 | 0.78 | AR (0.36) | ARALDH1A1KDM4EAOC3CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2014-12-18 | — | — | US | disclosed |
| US-8779129-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | AR 2826/4885ALDH1A1 3515/4885IMPDH2 4284/4885 |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | AR 2826/4885ALDH1A1 3515/4885IMPDH2 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.